252 related articles for article (PubMed ID: 17339601)
1. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?
Gao W; Dalton JT
Mol Interv; 2007 Feb; 7(1):10-3. PubMed ID: 17339601
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
3. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).
Gao W; Dalton JT
Drug Discov Today; 2007 Mar; 12(5-6):241-8. PubMed ID: 17331889
[TBL] [Abstract][Full Text] [Related]
4. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.
Narayanan R; Coss CC; Yepuru M; Kearbey JD; Miller DD; Dalton JT
Mol Endocrinol; 2008 Nov; 22(11):2448-65. PubMed ID: 18801930
[TBL] [Abstract][Full Text] [Related]
5. Selective androgen receptor modulators: in pursuit of tissue-selective androgens.
Omwancha J; Brown TR
Curr Opin Investig Drugs; 2006 Oct; 7(10):873-81. PubMed ID: 17086931
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
7. Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
Nejishima H; Yamamoto N; Suzuki M; Furuya K; Nagata N; Yamada S
Prostate; 2012 Oct; 72(14):1580-7. PubMed ID: 22430536
[TBL] [Abstract][Full Text] [Related]
8. Novel 17 substituted pregnadiene derivatives as 5 alpha-reductase inhibitors and their binding affinity for the androgen receptor.
Cabeza M; Flores E; Heuze I; Sánchez M; Bratoeff E; Ramírez E; Francolugo VA
Chem Pharm Bull (Tokyo); 2004 May; 52(5):535-9. PubMed ID: 15133203
[TBL] [Abstract][Full Text] [Related]
9. Development of selective androgen receptor modulators and their therapeutic applications.
Chen F; Rodan GA; Schmidt A
Zhonghua Nan Ke Xue; 2002; 8(3):162-8. PubMed ID: 12478835
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
11. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
12. Effect of a novel steroid (PM-9) on the inhibition of 5alpha-reductase present in Penicillium crustosum broths.
Flores E; Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E
Steroids; 2003 Mar; 68(3):271-5. PubMed ID: 12628690
[TBL] [Abstract][Full Text] [Related]
13. Androgen action: molecular mechanism and medical application.
Liao S
J Formos Med Assoc; 1994 Sep; 93(9):741-51. PubMed ID: 7735002
[TBL] [Abstract][Full Text] [Related]
14. Selective androgen receptor modulators as function promoting therapies.
Bhasin S; Jasuja R
Curr Opin Clin Nutr Metab Care; 2009 May; 12(3):232-40. PubMed ID: 19357508
[TBL] [Abstract][Full Text] [Related]
15. Prostate diseases--role of sex steroids and their inhibitors.
Welén K; Damber JE
Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
[TBL] [Abstract][Full Text] [Related]
16. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
17. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
18. Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator.
Zhang X; Allan GF; Tannenbaum P; Sbriscia T; Linton O; Lai MT; Haynes-Johnson D; Bhattacharjee S; Lundeen SG; Sui Z
J Steroid Biochem Mol Biol; 2013 Mar; 134():51-8. PubMed ID: 23098693
[TBL] [Abstract][Full Text] [Related]
19. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
Hsieh JT; Chen SC; Yu HJ; Chang HC
Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the development of selective androgen receptor modulators.
Zhang X; Lanter JC; Sui Z
Expert Opin Ther Pat; 2009 Sep; 19(9):1239-58. PubMed ID: 19505196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
